FilingReader Intelligence

Yifan Pharmaceutical subsidiary receives drug registration acceptance

July 17, 2025 at 05:17 PM UTC•By FilingReader AI

Yifan Pharmaceutical's subsidiary Suzhou Yifan Pharmaceutical received acceptance for its oral sodium phenylbutyrate drug registration. The drug, used for urea cycle disorders, generated global sales of $71.05 million in 2024.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Announcement regarding the wholly-owned subsidiary's receipt of the drug registration application acceptance noticeJuly 17, 2025 at 08:00 AM UTC

Supplementary Source Documents

Progress announcement on the inter-subsidiary adjustment of guarantee limits and providing guarantees for wholly-owned subsidiariesJuly 17, 2025 at 08:00 AM UTC

Yifan Pharmaceutical

SZSE:002019•Shenzhen Stock Exchange

RSS feed for Yifan Pharmaceutical

News Alerts

Get instant email alerts when Yifan Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →